WEST CHESTER, PA — Centinel Spine®, LLC, a leader in total disc replacement (TDR) technology, announced worldwide revenue exceeding $32 million for the third quarter of 2025—a 42% increase over the same period last year. The company also achieved record performance in its cervical TDR product segment, driven by surging demand and key regulatory approvals.
Worldwide prodisc® TDR revenue surpassed $30 million for the second consecutive quarter, while global prodisc Cervical TDR revenue reached nearly $20 million, marking a 34% year-over-year increase. Lumbar product sales climbed 58%, totaling more than $12 million. U.S. revenue rose 46% to nearly $27 million, and international sales exceeded $5 million, up 28%.
The company reported record EBITDA and sustained double-digit EBITDA margins for the fourth straight quarter, reflecting strong operational execution and continued market adoption of its spine implant technologies.
“Our continued momentum reflects the exceptional dedication of our team and the growing global demand for our prodisc technology,” said Steve Murray, CEO of Centinel Spine. “Achieving strong revenue growth and double-digit EBITDA margins, along with landmark regulatory milestones—such as 2-level FDA PMA approval and MDR certification for our key cervical products—reinforces our position as the global leader in total disc replacement. As more surgeons adopt our cervical and lumbar technologies and our international presence expands, we remain committed to transforming patient care with the most clinically proven total disc replacement solutions in the world.”
Recent milestones have strengthened Centinel Spine’s market position. The U.S. Food and Drug Administration granted Premarket Approval for two-level indications for the prodisc C Vivo and prodisc C SK devices, while the European Union awarded MDR certification for the prodisc C Vivo and prodisc C Nova systems.
Centinel Spine now works with more than 940 U.S. surgeons, nearly 50% more than a year ago—a testament to its accelerating adoption across hospitals and surgical centers.
With these advances, the company expects its robust growth trajectory to continue into the fourth quarter of 2025 as demand for motion-preserving spinal solutions continues to expand worldwide.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.